What are the primary FDA approval pathways for drugs, biologics, and medical devices?

The FDA uses different approval routes depending on the product. Drugs typically move through an IND followed by an NDA, while biologics progress through an IND and then a BLA due to their complexity. Medical devices are regulated based on risk and may require 510(k) clearance, De Novo classification, or Premarket Approval. Knowing the right pathway early helps streamline development.

What strategic elements play the biggest role in achieving FDA approval?

Success with the FDA depends on early regulatory planning, frequent communication with the agency, a clear Target Product Profile, strong manufacturing controls, and well-prepared clinical and nonclinical strategies. Companies that take a proactive approach generally face fewer regulatory challenges.

How is the regulatory evaluation of biologics different from that of traditional small-molecule drugs?

Biologics are derived from living systems and are more sensitive to manufacturing changes. Their regulatory pathway usually involves a BLA and requires extensive analytical, clinical, and quality data. In contrast, small-molecule drugs follow the NDA pathway and rely more on chemical characterization and controlled synthesis.

What challenges do companies commonly face when navigating FDA approval?

Common challenges include unclear regulatory pathways, inadequate manufacturing readiness, insufficient clinical planning, delayed FDA engagement, and lack of preparedness for inspections or global regulatory coordination. These issues often lead to delays or additional information requests.

In what ways does the roadmap to FDA approval differ between drug and device development?

While both involve preclinical work, human studies, submission, and post-market activities, their requirements differ greatly. Drug and biologic programs emphasize clinical trials and detailed CMC data. Devices may focus more on engineering testing, software validation, and human factors, and may rely on predicate devices for 510(k) submissions.

Mastering the FDA STAR Program for Faster Drug Approvals

Bringing innovative therapies to patients requires more than strong clinical evidence—it demands an effective regulatory strategy that aligns with evolving U.S. Food and Drug Administration (FDA) expectations. To improve the efficiency of regulatory reviews while maintaining rigorous standards for safety, efficacy, and product quality, the FDA introduced the Split Real-Time Application Review (STAR) Program under the Prescription Drug User Fee Act (PDUFA VII). The program provides eligible sponsors with an opportunity to submit portions of a marketing application before the complete submission is finalized, allowing FDA reviewers to begin evaluating critical information earlier in the review process. Organizations seeking to accelerate product approvals should understand how the FDA STAR Program works, its eligibility requirements, and the strategic planning necessary to maximize its benefits.

Unlike the traditional review process, where FDA evaluation begins only after receiving a complete application, the STAR Program allows sponsors to divide eligible efficacy supplements into two coordinated submissions. This approach enables FDA review teams to assess substantial portions of the application in advance while the remaining components are being finalized. Although the official review timeline begins only after the complete application has been received, the earlier assessment of submitted information can improve review efficiency and facilitate more timely regulatory interactions. The STAR Program reflects FDA’s commitment to modernizing regulatory pathways without compromising scientific rigor or patient safety.

Participation in the STAR Program is limited to specific supplemental New Drug Applications (sNDAs) and supplemental Biologics License Applications (sBLAs) that meet FDA eligibility criteria. These applications generally involve new indications for approved products intended to treat serious conditions where the proposed therapy has the potential to provide a significant improvement over currently available treatment options. Sponsors must demonstrate that their application qualifies for Priority Review and satisfies the program’s submission requirements before FDA considers participation. Careful evaluation of eligibility criteria is essential to determine whether the STAR pathway is appropriate for a particular development program.

A successful Regulatory Submission Strategy begins long before the application reaches the FDA. Sponsors should integrate regulatory planning into every stage of product development, ensuring that clinical, statistical, manufacturing, quality, and medical writing teams remain aligned throughout the submission process. Preparing two coordinated submission packages requires careful project management, robust document control, and cross-functional collaboration to ensure that each component meets FDA expectations. Delays in document preparation or inconsistencies between submission packages may reduce the operational advantages that the STAR Program is designed to provide.

Submission quality remains one of the most important factors influencing review efficiency. Applications should include well-organized clinical data, validated statistical analyses, comprehensive summaries, accurate labeling proposals, and complete chemistry, manufacturing, and controls (CMC) documentation. High-quality electronic submissions reduce the likelihood of information requests and facilitate a smoother review process. Sponsors should also conduct internal quality reviews before each submission to verify that documentation is complete, accurate, and compliant with FDA technical requirements.

Effective communication with the FDA is another critical component of a successful STAR submission. Sponsors are encouraged to engage with the Agency through formal meetings and regulatory interactions to discuss submission readiness, eligibility, and review expectations. Early communication helps clarify regulatory requirements, identify potential concerns, and establish realistic timelines for submission. Maintaining open dialogue throughout the review process enables sponsors to respond efficiently to FDA questions and support timely decision-making.

Cross-functional collaboration is equally important in ensuring successful participation in the STAR Program. Regulatory affairs professionals, clinical development teams, biostatisticians, quality assurance specialists, manufacturing experts, pharmacovigilance personnel, and medical writers must coordinate their activities to maintain consistency across all submission components. Strong governance structures, clearly defined responsibilities, and effective communication channels help organizations manage complex submission timelines while minimizing regulatory risk.

Sponsors should recognize that the STAR Program is not intended for every regulatory submission. Organizations must carefully assess product maturity, data readiness, manufacturing status, and available internal resources before selecting this pathway. A comprehensive readiness assessment allows sponsors to determine whether they can successfully support a split submission while maintaining the high-quality documentation expected by FDA reviewers. Selecting the appropriate regulatory pathway remains a strategic decision that should align with both business objectives and regulatory expectations.

As FDA continues to modernize its review processes, the STAR Program represents an important opportunity for eligible sponsors to improve submission efficiency while maintaining the highest standards of scientific review. Organizations that understand the requirements of the FDA STAR Program, develop a comprehensive Regulatory Submission Strategy, and prepare high-quality Priority Review Applications are better positioned to navigate complex regulatory pathways and accelerate access to innovative therapies. Strategic planning, submission excellence, and proactive regulatory engagement remain essential for achieving successful outcomes and supporting timely patient access to safe and effective medical products.

Register now to master the FDA STAR Program,Regulatory Submission Strategy, and Priority Review Applications for faster FDA approvals.

Frequently Asked Questions

1. Which applications are eligible for participation in the FDA STAR Program?

The STAR Program is currently available for eligible supplemental New Drug Applications (sNDAs) and supplemental Biologics License Applications (sBLAs) seeking approval for new indications that meet FDA eligibility requirements, including Priority Review designation.

2. How does the FDA STAR Program differ from the traditional application review process?

Unlike the traditional review process, the STAR Program allows eligible sponsors to submit qualifying application components in two parts, enabling FDA reviewers to begin evaluating key information before the complete submission is received.

3. What factors should sponsors evaluate before requesting participation in the STAR Program?

Sponsors should assess product eligibility, clinical data maturity, submission readiness, manufacturing documentation, electronic submission quality, and internal resource availability to determine whether the STAR pathway aligns with their regulatory strategy.

4. What are the critical success factors for an effective STAR Program submission?

Successful participation depends on comprehensive regulatory planning, high-quality submission documentation, cross-functional collaboration, robust project management, and proactive communication with the FDA throughout the review process.

5. How can the STAR Program support a more efficient FDA review?

By allowing FDA reviewers to evaluate portions of an eligible application before the complete submission is received, the STAR Program can improve review efficiency, facilitate earlier regulatory interactions, and support timely decision-making while maintaining FDA's scientific and regulatory standards.